Congenital hypertrophy of the retinal pigment epithelium presenting with secondary choroidal neovascularization

Robert B. Garoon; J. William Harbour

doi:10.3928/23258160-20180329-12

Congenital hypertrophy of the retinal pigment epithelium presenting with secondary choroidal neovascularization

Robert B. Garoon, J. William Harbour

Ophthalmology

Research output: Contribution to journal › Article

Abstract

The authors report a case of a congenital hypertrophy of the retinal pigment epithelium (CHRPE) associated with choroidal neovascularization (CNV) causing symptomatic vision loss. Two intravitreal injections of bevacizumab (Avastin; Genentech, South San Francisco, CA) 4 weeks apart resolved the fluid and improved the visual acuity. This case demonstrates that CHRPE can rarely be complicated by CNV, which may respond to intravitreal bevacizumab therapy.

Original language	English (US)
Pages (from-to)	276-277
Number of pages	2
Journal	Ophthalmic Surgery Lasers and Imaging Retina
Volume	49
Issue number	4
DOIs	https://doi.org/10.3928/23258160-20180329-12
State	Published - Apr 1 2018

Fingerprint

ASJC Scopus subject areas

Surgery
Ophthalmology

Cite this

Garoon, R. B., & William Harbour, J. (2018). Congenital hypertrophy of the retinal pigment epithelium presenting with secondary choroidal neovascularization. Ophthalmic Surgery Lasers and Imaging Retina, 49(4), 276-277. https://doi.org/10.3928/23258160-20180329-12

@article{d657ed44b1ca4e74aa202a4a71a22043,

title = "Congenital hypertrophy of the retinal pigment epithelium presenting with secondary choroidal neovascularization",

abstract = "The authors report a case of a congenital hypertrophy of the retinal pigment epithelium (CHRPE) associated with choroidal neovascularization (CNV) causing symptomatic vision loss. Two intravitreal injections of bevacizumab (Avastin; Genentech, South San Francisco, CA) 4 weeks apart resolved the fluid and improved the visual acuity. This case demonstrates that CHRPE can rarely be complicated by CNV, which may respond to intravitreal bevacizumab therapy.",

author = "Garoon, {Robert B.} and {William Harbour}, J.",

year = "2018",

month = apr

day = "1",

doi = "10.3928/23258160-20180329-12",

language = "English (US)",

volume = "49",

pages = "276--277",

journal = "Ophthalmic Surgery Lasers and Imaging Retina",

issn = "2325-8160",

publisher = "Slack Incorporated",

number = "4",

}

TY - JOUR

T1 - Congenital hypertrophy of the retinal pigment epithelium presenting with secondary choroidal neovascularization

AU - Garoon, Robert B.

AU - William Harbour, J.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - The authors report a case of a congenital hypertrophy of the retinal pigment epithelium (CHRPE) associated with choroidal neovascularization (CNV) causing symptomatic vision loss. Two intravitreal injections of bevacizumab (Avastin; Genentech, South San Francisco, CA) 4 weeks apart resolved the fluid and improved the visual acuity. This case demonstrates that CHRPE can rarely be complicated by CNV, which may respond to intravitreal bevacizumab therapy.

AB - The authors report a case of a congenital hypertrophy of the retinal pigment epithelium (CHRPE) associated with choroidal neovascularization (CNV) causing symptomatic vision loss. Two intravitreal injections of bevacizumab (Avastin; Genentech, South San Francisco, CA) 4 weeks apart resolved the fluid and improved the visual acuity. This case demonstrates that CHRPE can rarely be complicated by CNV, which may respond to intravitreal bevacizumab therapy.

UR - http://www.scopus.com/inward/record.url?scp=85046129595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046129595&partnerID=8YFLogxK

U2 - 10.3928/23258160-20180329-12

DO - 10.3928/23258160-20180329-12

M3 - Article

C2 - 29664987

AN - SCOPUS:85046129595

VL - 49

SP - 276

EP - 277

JO - Ophthalmic Surgery Lasers and Imaging Retina

JF - Ophthalmic Surgery Lasers and Imaging Retina

SN - 2325-8160

IS - 4

ER -

Access to Document

10.3928/23258160-20180329-12